Fig. 1: Clinical information of 521 glioma patients. | Cell Death Discovery

Fig. 1: Clinical information of 521 glioma patients.

From: IDH1-mutant metabolite D-2-hydroxyglutarate inhibits proliferation and sensitizes glioma to temozolomide via down-regulating ITGB4/PI3K/AKT

Fig. 1

A Initial Symptoms in Glioma Patients. Among 521 glioma patients, the most prevalent initial symptoms were dizziness and headache, accounting for 39.54%. Seizures were reported in 18.81% of cases, while limb movement and sensory abnormalities were observed in 15.16% of patients. B Among 521 cases of glioma, patients with IDH1 mutations had a longer progression-free survival (PFS) compared to those with wild-type IDH1, with a median PFS of 4.05 years compared to 1.21 years (P < 0.001). C Among 275 cases of low-grade gliomas (LGG), patients with IDH1 mutations had a median PFS of 4.26 years compared to 1.62 years for those with wild-type IDH1 (P < 0.001). D Among 246 cases of high-grade gliomas (HGG), patients with IDH1 mutations had a median PFS of 2.74 years compared to 1.16 years for those with wild-type IDH1 (P < 0.001). E Patients with IDH1-mutant gliomas had significantly longer progression-free survival (PFS) than those with IDH1 wild-type gliomas (P < 0.001), and TMZ treatment did not affect the PFS within IDH1-mutant and wild-type glioma groups. F In low-grade gliomas (LGG), TMZ extended the median PFS of patients with IDH1-mutant gliomas from 3.55 years to 5.3 years (P < 0.001), while it had no impact on the PFS of patients with IDH1 wild-type gliomas. G In high-grade gliomas (HGG), TMZ had no effect on the PFS of patients with IDH1 wild-type gliomas, and there were no cases of IDH1-mutant HGG that did not receive TMZ, so the treatment effect of TMZ on IDH1-mutant HGG was not analyzed.

Back to article page